NCT00373776View on ClinicalTrials.gov

Miltefosine for Mucosal Leishmaniasis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

May 31, 2006

Conditions

Leishmaniasis

Interventions

DRUG

miltefosine 2.5 mg/kg/day for 28 days

Trial Locations (1)

Unknown

Palos Blancos

All Listed Sponsors

lead

AB Foundation

OTHER

NCT00373776 - Miltefosine for Mucosal Leishmaniasis | Biotech Hunter | Biotech Hunter